Envestnet Asset Management Inc. Purchases 21,307 Shares of Celldex Therapeutics, Inc. $CLDX

Envestnet Asset Management Inc. boosted its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 50.4% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 63,594 shares of the biopharmaceutical company’s stock after purchasing an additional 21,307 shares during the quarter. Envestnet Asset Management Inc.’s holdings in Celldex Therapeutics were worth $1,645,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently made changes to their positions in CLDX. Nisa Investment Advisors LLC increased its holdings in shares of Celldex Therapeutics by 171.7% in the second quarter. Nisa Investment Advisors LLC now owns 1,394 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 881 shares during the period. Wilmington Savings Fund Society FSB purchased a new position in Celldex Therapeutics during the third quarter worth about $42,000. Russell Investments Group Ltd. increased its stake in Celldex Therapeutics by 27.6% in the 2nd quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock worth $47,000 after acquiring an additional 501 shares during the last quarter. Strs Ohio bought a new position in Celldex Therapeutics in the 3rd quarter worth about $75,000. Finally, Headlands Technologies LLC purchased a new stake in shares of Celldex Therapeutics in the 2nd quarter valued at about $125,000.

Key Celldex Therapeutics News

Here are the key news stories impacting Celldex Therapeutics this week:

• Positive Sentiment: New Phase 2 clinical data for barzolvolimab presented at AAAAI show sustained off‑treatment efficacy in chronic spontaneous urticaria (CSU) and meaningful quality‑of‑life gains in cold urticaria/symptomatic dermographism — potential upside for future regulatory/label discussions and commercial prospects. Celldex Presents Additional Positive Data
• Positive Sentiment: Analyst bullishness: Stifel reaffirmed a Buy and raised its price target to $68, and Morgan Stanley reiterated a Buy — these upgrades/support increase the stock’s upside narrative for investors focused on clinical catalysts. Stifel Reaffirms Buy, Raises PT
• Positive Sentiment: Sell‑side coverage remains constructive overall (average rating around “Moderate Buy”), which can sustain interest into upcoming 2026 data readouts and EMBARQ enrollment updates. TipRanks / Analyst Note
• Neutral Sentiment: HC Wainwright published EPS forecasts for FY2026/FY2027 (negative EPS expected), providing modeling detail but no change in clinical outlook; useful for valuation but not an immediate catalyst. HC Wainwright Estimates (MarketBeat)
• Neutral Sentiment: Mixed media and analyst commentary (Beaumont Enterprise, AmericanBankingNews) reinforce analyst interest but do not add new clinical or financial surprises. Q4 Snapshot
• Negative Sentiment: Recent Q4 2025 financials disappointed: the company missed EPS and revenue expectations, reported very large negative margins and negative ROE, and consensus still expects meaningful losses for 2026 — headwinds for near‑term sentiment and valuation. Q4 and Year‑End 2025 Results
• Negative Sentiment: Short interest data posted recently are inconsistent/odd (reported as zero), which may create temporary noise but reflects no clear short‑pressure signal.

Celldex Therapeutics Trading Down 1.8%

Shares of NASDAQ CLDX opened at $30.09 on Friday. The stock’s 50-day moving average is $25.70 and its 200 day moving average is $25.52. The stock has a market cap of $2.00 billion, a price-to-earnings ratio of -7.74 and a beta of 1.24. Celldex Therapeutics, Inc. has a 1-year low of $14.40 and a 1-year high of $31.31.

Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings results on Wednesday, February 25th. The biopharmaceutical company reported ($1.22) EPS for the quarter, missing analysts’ consensus estimates of ($1.00) by ($0.22). The business had revenue of $0.12 million for the quarter, compared to the consensus estimate of $1.53 million. Celldex Therapeutics had a negative net margin of 3,446.88% and a negative return on equity of 39.67%. On average, analysts forecast that Celldex Therapeutics, Inc. will post -2.48 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently commented on CLDX shares. Stifel Nicolaus reissued a “buy” rating and set a $68.00 price objective (up from $58.00) on shares of Celldex Therapeutics in a report on Thursday. Barclays lifted their target price on shares of Celldex Therapeutics from $21.00 to $24.00 and gave the company an “underweight” rating in a research report on Wednesday, December 17th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Celldex Therapeutics in a report on Wednesday, January 21st. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $44.20.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.